TanCSchatzRA.The history of coronary stenting. Interv Cardiol Clin. 2016;5:271–280.
2.
TorradoJBuckleyLDuránAet al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. J Am Coll Cardiol. 2018;71:1676–1695.
3.
GiordanoAMusumeciGD’AngelilloAet al. Effects of glycoprotein IIb/IIIa antagonists: antiplatelet aggregation and beyond. Curr Drug Metab. 2016;17:194–203.
4.
PalmeriniTBiondi-ZoccaiGDella RivaDet al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299–307.
5.
CapodannoD.Bioresorbable scaffolds in coronary intervention: unmet needs and evolution. Korean Circ J. 2018;48:24–35.
6.
BangaloreSBezerraHGRizikDGet al. The state of the Absorb bioresorbable scaffold: consensus from an expert panel. JACC Cardiovasc Interv. 2017;10:2349–2359.
7.
RegazzoliDLeonePPColomboAet al. New generation bioresorbable scaffold technologies: an update on novel devices and clinical results. J Thorac Dis. 2017;9(suppl 9):S979–S985.
8.
EllisSGKereiakesDJMetzgerDCet al.;ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–1915.
9.
MahmoudANBarakatAFElgendyAYet al. Long-term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2017;10:e005286.
10.
VarcoeRLSchoutenOThomasSDet al. Initial experience with the absorb bioresorbable vascular scaffold below the knee: six-month clinical and imaging outcomes. J Endovasc Ther. 2015;22:226–232.
11.
VarcoeRLSchoutenOThomasSDet al. Experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes. JACC Cardiovasc Interv. 2016;9:1721–1728.
12.
VarcoeRLThomasSDLennoxAF.Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25:694–701.
13.
DeRubertisBGKumSVarcoeRL.Editorial: The demise of the Absorb BVS: lessons learned from the discontinuation of a disappearing stent. J Endovasc Ther. 2018;25:706–709.
14.
VarcoeRLThomasSDRapozaRet al. Lessons learned regarding handling and deployment of the Absorb Bioresorbable Vascular Scaffold in infrapopliteal arteries. J Endovasc Ther. 2017;24:337–341.
15.
GiordanoAMessinaSBiondi-ZoccaiG.Successful treatment of a subclavian artery stenosis with a coronary bioresorbable vascular scaffold. J Endovasc Ther. 2016;23:653–656.
16.
GiordanoAFerraroPCorcioneNet al. Endovascular therapy for infrainguinal artery disease with coronary devices: a retrospective observational study comparing drug-eluting stents versus bioresorbable vascular scaffolds. Angiology. 2017;68:59–66.
17.
GiordanoAFerraroPCorcioneNet al. Successful treatment of recurrent carotid in-stent restenosis and drug-eluting balloon failure with a coronary bioresorbable vascular scaffold: A case report. Int J Surg Case Rep. 2016;21:78–82.
18.
OnumaYSerruysPWPerkinsLEet al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bio-resorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human. Circulation. 2010;122:2288–2300.
19.
DakeMDAnselGMJaffMRet al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
20.
BradenGAXenopoulosNPYoungTet al. Transluminal extraction catheter atherectomy followed by immediate stenting in treatment of saphenous vein grafts. J Am Coll Cardiol. 1997;30:657–663.
